Chugai And Nippon Kayaku Drugs Benefit From Japan’s New Fast Track Review Process
This article was originally published in PharmAsia News
Chugai Pharmaceutical's Xeloda (capecitabine) and Nippon Kayaku's Hycamtin (nogitecan) are to benefit from a new fast review process installed by Japan's Ministry of Health, Labor and Welfare to accelerate the approval process for drugs with high medical need
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.